The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Open accessAbstract
Key Points: Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Data from a number of in vitro studies support the hypothesis that thalidomide analogues synergize with dexamethasone49,50, proteasome inhibitors51,52, histone deacetylase inhibitors53,54 and a variety of other agents”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationBladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationHideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874
Self-citationPrevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citationMiguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806
Self-citationCorral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 792
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
Research works printed but not linked: 1
- Rychack, 2011, Overcoming resistance; the use of pomalidomide (POM) and dexamethasone (DEX) in re-sensitizing lenalidomide (LEN)-resistant multiple myeloma (MM) cells., Haematologica, 96, S126
Cited by
Sorted by citations
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citationDiagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 830
Attal, M., Richardson, P. G. G., Rajkumar, S. V., Miguel, J. F. S., Beksaç, M., Špıčka, I., Leleu, X. P., Schjesvold, F. H., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 648
Self-citationElotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X. P., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805762 · Cited by 540
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 466
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A. Y., Lentzsch, S., Comenzo, R. L., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 444
Self-citationUsmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
Argyriou, A. A., Kyritsis, A. P., Makatsoris, T., & Kalofonos, H. P. (2014) · Cancer Management and Research · doi:10.2147/cmar.s44261 · Cited by 279
Spencer, A. G., Lentzsch, S., Weisel, K. C., Avet‐Loiseau, H., Mark, T. M., Špıčka, I., Masszi, T., Lauri, B., Levin, M., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 271
Self-citationPanobinostat for the Treatment of Multiple Myeloma
Laubach, J. P., Moreau, P., Miguel, J. F. S., & Richardson, P. G. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0530 · Cited by 273
Self-citationImmunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 263
Trudel, S., Lendvai, N. K., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G. G., Anderson, L. D., Sutherland, H. J., Yong, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30576-x · Cited by 255
Self-citationMultiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 229
Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 215
Current treatment landscape for relapsed and/or refractory multiple myeloma
Dimopoulos, M. A., Richardson, P. G. G., Moreau, P., & Anderson, K. C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.200 · Cited by 197
Self-citationNovel agents in the treatment of multiple myeloma: a review about the future
Naymagon, L., & Abdul‐Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 180
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Sanchez, L. J., Wang, Y., Siegel, D. S. D., & Wang, M. L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0283-0 · Cited by 178
Self-citationTreatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
Progress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 173
Self-citationDimopoulos, M. A., Palumbo, A. P., Corradini, P., Cavo, M., Delforge, M., Raimondo, F. D., Weisel, K. C., Oriol, A., Hansson, M., Vacca, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700872 · Cited by 165
Self-citationMyeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2015) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 163
Baz, R., Martin, T. G., Lin, H., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A. K., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 161
Self-citationTreatment options for relapsed and refractory multiple myeloma
Nooka, A. K., Kastritis, E., Dimopoulos, M. A., & Lonial, S. (2015) · Blood · doi:10.1182/blood-2014-11-568923 · Cited by 157
Self-citationNephrotoxicity in cancer treatment: An overview
Santos, M. L. C., de Brito, B. B., da Silva, F. A. F., Botelho, A. C. D. S., & de Melo, F. F. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i4.190 · Cited by 157
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw606 · Cited by 153
Self-citationSpencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood · doi:10.1182/blood-2014-03-559963 · Cited by 142
Self-citationTherapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 144
Self-citationUsmani, S. Z., Ahmadi, T., Ng, Y., Lam, A., Desai, A. G., Potluri, R. C., & Mehra, M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0104 · Cited by 139
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Sehgal, K., Das, R., Zhang, L., Verma, R., Deng, Y., Kocoglu, M. H., Vasquez, J. C., Koduru, S. V., Ren, Y., Wang, M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611426 · Cited by 134
Richardson, P. G. G., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2015) · Blood · doi:10.1182/blood-2015-09-665018 · Cited by 133
Self-citationDimopoulos, M. A., Leleu, X. P., Palumbo, A. P., Moreau, P., Delforge, M., Cavo, M., Ludwig, H., Morgan, G. J., Davies, F. E., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.60 · Cited by 125
Song, Y., Li, S., Ray, A., Das, D. S., Qi, J., Samur, M., Tai, Y., Munshi, N. C., Carrasco, R. D., Chauhan, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.172 · Cited by 112
Self-citationCurrent Trends of Renal Impairment in Multiple Myeloma
Yadav, P., Cook, M. A., & Cockwell, P. (2015) · Kidney Diseases · doi:10.1159/000442511 · Cited by 115
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Martin, T. G., Strickland, S. A., Glenn, M. J., Charpentier, E., Guillemin, H., Hsu, K., & Mikhael, J. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0198-4 · Cited by 109
Self-citationManagement of multiple myeloma in the relapsed/refractory patient
Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 110
Cornell, R. F., & Kassim, A. A. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.307 · Cited by 102
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies
Li, W., Garcia, D. A., Cornell, R. F., Gailani, D., Laubach, J. P., Maglio, M. E., Richardson, P. G. G., & Moslehi, J. J. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3350 · Cited by 103
Self-citationLeleu, X. P., Karlin, L., Macro, M., Hulin, C., Garderet, L., Roussel, M., Arnulf, B., Pegourié, B., Kolb, B., Stoppa, A. M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612069 · Cited by 100
Bispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 106
Self-citationA phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis
Palladini, G. O., Milani, P., Foli, A., Basset, M., Russo, F., Perlini, S., & Merlini, G. (2017) · Blood · doi:10.1182/blood-2016-12-756528 · Cited by 93
Pulte, D. D., Jansen, L., Castro, F. A., Emrich, K., Katalinic, A., Holleczek, B., Brenner, H., & the GEKID Cancer Survival Working Group (2015) · British Journal of Haematology · doi:10.1111/bjh.13537 · Cited by 92
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 90
Mikhael, J. R., Richardson, P. G. G., Usmani, S. Z., Raje, N. S., Bensinger, W., Karanes, C., Campana, F., Kanagavel, D., Dubin, F., Liu, Q., et al. (2019) · Blood · doi:10.1182/blood-2019-02-895193 · Cited by 90
Self-citationPromising therapies in multiple myeloma
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 86
Self-citationAcademic, Foundation, and Industry Collaboration in Finding New Therapies
Ramsey, B. W., Nepom, G. T., & Lonial, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1612575 · Cited by 87
Self-citationRichardson, P. G. G., Bringhen, S., Voorhees, P. M., Plesner, T., Mellqvist, U., Reeves, B., Paba‐Prada, C. E., Zubair, H., Byrne, C., Chauhan, D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30044-2 · Cited by 83
Self-citationSiegel, D. S. D., Schiller, G. J., Samaras, C. J., Sébag, M., Berdeja, J. G., Ganguly, S., Matous, J., Song, K., Seet, C. S., Talamo, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0813-1 · Cited by 84
Self-citationPaludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S. K., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Lust, J. A., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782961 · Cited by 78
Self-citationApproach to chemotherapy-associated thrombosis
Oppelt, P., Betbadal, A., & Nayak, L. V. (2015) · Vascular Medicine · doi:10.1177/1358863x14568705 · Cited by 76
Spencer, A. G., Harrison, S. J., Zonder, J. A., Badros, A. Z., Laubach, J. P., Bergin, K., Khot, A. S., Zimmerman, T. M., Chauhan, D., Levin, N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14987 · Cited by 73
Self-citationDimopoulos, M. A., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117077 · Cited by 72
Self-citationMoreau, P., Dimopoulos, M. A., Yong, K., Mikhael, J. R., Risse, M., Asset, G., & Martin, T. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0431 · Cited by 72
Self-citationRichardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71
Self-citationJakubowiak, A. J., Jasielec, J. K., Rosenbaum, C. A., Cole, C. E., Chari, A., Mikhael, J. R., Nam, J., McIver, A., Severson, E., Stephens, L. A., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15969 · Cited by 69
Self-citationMultiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
Fotiou, D., Gavriatopoulou, M., & Terpos, E. (2020) · Cancers · doi:10.3390/cancers12010191 · Cited by 69
Dimopoulos, M. A., Weisel, K. C., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M. J., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.1742 · Cited by 69
How I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Pain in cancer survivors; filling in the gaps
Brown, M. R. D., & Farquhar-Smith, P. W. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex202 · Cited by 71
Shah, J. J., Kaufman, J. L., Zonder, J. A., Cohen, A. D., Bensinger, W., Hilder, B. W., Rush, S. A., Walker, D. H., Tunquist, B. J., Litwiler, K. S., et al. (2017) · Cancer · doi:10.1002/cncr.30892 · Cited by 65
Self-citationPomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre‐Barbe, M., Lafon, I., Facon, T. T. F., Leleu, X. P., Karlin, L., Perrot, A., et al. (2018) · Blood · doi:10.1182/blood-2018-07-863829 · Cited by 65
Kazandjian, D. G., & Landgren, O. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.008 · Cited by 63
Dimopoulos, M. A., Weisel, K. C., Moreau, P., Anderson, L. D., White, D. J., Miguel, J. F. S., Sonneveld, P., Engelhardt, M. M., Jenner, M. W., Corso, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01021-3 · Cited by 64
Self-citationBraunlin, M., Belani, R., Buchanan, J., Wheeling, J. T., & Kim, C. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1827253 · Cited by 63
Rychak, E., Mendy, D., Shi, T., Ning, Y., Leisten, J. C., Lu, L., Miller, K., Narla, R. K., Orlowski, R. Z., Raymon, H. K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13905 · Cited by 61
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
Wanchoo, R., Abudayyeh, A., Doshi, M. D., Edeani, A., Glezerman, I. G., Monga, D., Rosner, M. H., & Jhaveri, K. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06100616 · Cited by 61
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 59
Current treatments for renal failure due to multiple myeloma
Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236915 · Cited by 54
Cereblon binding molecules in multiple myeloma
Kortüm, K. M., Zhu, Y. X., Shi, C., Jedlowski, P. M., & Stewart, A. K. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.003 · Cited by 53
Hideshima, T., Cottini, F., Nozawa, Y., Seo, H., Ohguchi, H., Samur, M., Cirstea, D. D., Mimura, N., Iwasawa, Y., Richardson, P. G. G., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738500 · Cited by 56
Self-citationRamasamy, K., Gay, F., Weisel, K. C., Zweegman, S., Mateos, M., & Richardson, P. G. G. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100808 · Cited by 55
Self-citationMiguel, J. F. S., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125864 · Cited by 51
Self-citationMonoclonal antibodies — A new era in the treatment of multiple myeloma
Jelı́nek, T., & Hájek, R. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.004 · Cited by 50
Krishnan, A. Y., Kapoor, P., Palmer, J. M., Tsai, N., Kumar, S. K., Lonial, S., Htut, M., Karanes, C., Nathwani, N., Rosenzweig, M. A., et al. (2017) · Leukemia · doi:10.1038/s41375-018-0038-8 · Cited by 56
Self-citationDas, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13780 · Cited by 49
Self-citationStefano, V. D., Larocca, A., Carpenedo, M., Cavo, M., Raimondo, F. D., Falanga, A., Offidani, M., Petrucci, M. T., Ruggeri, M., Santi, R. M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280893 · Cited by 52
Raheja, D., Specht, C., & Simmons, Z. (2014) · Muscle & Nerve · doi:10.1002/mus.24471 · Cited by 49
Multiple Myeloma: From Front-Line to Relapsed Therapies
Moreau, P., & Touzeau, C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e504 · Cited by 48
Schmitz, S., Maguire, Á., Morris, J., Ruggeri, K., Haller, E., Kuhn, I. L., Leahy, J., Homer, N., Khan, A., Bowden, J., et al. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0509-7 · Cited by 49
New Agents in Multiple Myeloma: An Examination of Safety Profiles
Bringhen, S., de Wit, E., & Dimopoulos, M. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.003 · Cited by 49
Siegel, D. S., Schiller, G. J., Song, K. W., Agajanian, R., Stockerl‐Goldstein, K., Kaya, H., Sebag, M., Samaras, C., Malek, E., Talamo, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16213 · Cited by 46
Self-citationTreatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46
Self-citationEmerging drugs and combinations to treat multiple myeloma
Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 44
Pelligra, C. G., Parikh, K., Guo, S., Chandler, C., Mouro, J. L., Abouzaid, S., & Ailawadhi, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.010 · Cited by 46
Mechanisms of lenalidomide sensitivity and resistance
Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 48
Kelly, K. R., Ailawadhi, S., Siegel, D. S., Heffner, L. T., Somlo, G., Jagannath, S., Zimmerman, T. M., Munshi, N. C., Madan, S., Chanan-Khan, A., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00208-8 · Cited by 46
Self-citationPopulation pharmacokinetics of pomalidomide
Li, Y., Xu, Y., Liu, L., Wang, X., Palmisano, M., & Zhou, S. Y. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.455 · Cited by 44
Immunotherapy in Multiple Myeloma
Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 48
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
Ríos, R., Agustin, M.-G., Alarcón-Payer, C., Dolores, S.-R., María, V. D. D. L. G. A., Collado, C. G., Alberto, J. M., Manuel, J. C., & Barrera, J. C. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s115456 · Cited by 43
Kunacheewa, C., & Orlowski, R. Z. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-112017-091045 · Cited by 42
Pathogenesis and treatment of multiple myeloma
Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., & Qian, Z. (2022) · MedComm · doi:10.1002/mco2.146 · Cited by 46
Malek, E., Rana, P. S., Swamydas, M., Daunov, M., Miyagi, M., Murphy, E., Ignatz-Hoover, J. J., Metheny, L. L., Kim, S.-J., & Driscoll, J. J. (2024) · Nature Communications · doi:10.1038/s41467-024-51442-2 · Cited by 45
Metadata
- Authors
- Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., Song, K., Belch, A., Raje, N., Shustik, C., Lentzsch, S., Lacy, M., Mikhael, J., Matous, J., Vesole, D., Chen, M., Zaki, M. H., Jacques, C., Yu, Z., & Anderson, K. C.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Hackensack University Medical Center (US)
- Washington University in St. Louis (US)
- The Ohio State University (US)
- Moffitt Cancer Center (US)
- Mount Sinai Medical Center, New York, NY;
- Princess Margaret Cancer Centre (CA)
- Emory University (US)
- University of Chicago Medical Center (US)
- University of Calgary (CA)
- Vancouver General Hospital (CA)
- University of Alberta (CA)
- Massachusetts General Hospital (US)
- Royal Victoria Hospital (CA)
- Columbia University (US)
- Mayo Clinic (US)
- Colorado Blood Cancer Institute (US)
- Celgene (United States) (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-03-20
- Volume
- 123
- Issue
- 12
- Pages
- 1826-1832
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3962162
- OpenAlex
- W2091773528
- Cited by
- 381
- References
- 43
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 17 · 2023: 14 · 2022: 39 · 2021: 30 · 2020: 31 · 2019: 24 · 2018: 30 · 2017: 54 · 2016: 48 · 2015: 48 · 2014: 27
- FWCI
- 41.83
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-05-15)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Celgene
- National Cancer Institute (P50CA100707, P01CA155258, P30CA016058)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- pomalidomide, low-dose dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, lenalidomide-refractory disease, bortezomib resistance, combination therapy, neutropenia, peripheral neuropathy, overall survival, overall response rate
- MeSH terms
- Bortezomib, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Dexamethasone, Female, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Neutropenia, Pyrazines, Thalidomide, Treatment Outcome, Disease-Free Survival, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
